Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

By 1969, Gibson’s Maestro division contracted Oberheim Electronics to build his ring modulator for them, which was marketed as the Maestro RM-1A. The ring modulator had limited appeal to the masses ...

Because Krea relinquishes centralized control over the downstream deployment of its open weights, the contract legally binds ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the ...

Fine-scale exogenous attention within the foveola selectively enhances contrast gain at low-to-mid spatial frequencies while increasing response gain across a broad spatial frequency range.

Discusses Clinical Trials Growth Through Indication and Solution Expansion With Focus on Psychiatry and Narcolepsy June 9, ...